Oncternal Therapeutics, Inc. (ONCT) financial statements (2022 and earlier)
Company profile
| Business Address |
12230 EL CAMINO REAL SAN DIEGO, CA 92130 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 90,765 | 97,380 | 103,663 | 111,211 | 116,737 | 21,259 | ||
| Cash and cash equivalents | 90,765 | 97,380 | 103,663 | 111,211 | 116,737 | 21,259 | ||
| Prepaid expense | 1,266 | |||||||
| Other undisclosed current assets | 2,088 | 2,140 | 3,936 | 1,873 | 1,448 | |||
| Total current assets: | 92,853 | 99,520 | 107,599 | 113,084 | 118,003 | 22,707 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 75 | 119 | 162 | 204 | 40 | 79 | ||
| Other noncurrent assets | 657 | 657 | 658 | 769 | 766 | 766 | ||
| Total noncurrent assets: | 732 | 776 | 820 | 973 | 806 | 845 | ||
| TOTAL ASSETS: | 93,585 | 100,296 | 108,419 | 114,057 | 118,809 | 23,552 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 5,390 | 5,543 | 3,502 | 4,665 | 4,185 | 4,250 | ||
| Accounts payable | 1,959 | 2,746 | 1,009 | 1,892 | 1,143 | 977 | ||
| Accrued liabilities | 3,431 | 2,797 | 2,493 | 2,773 | 3,042 | 3,273 | ||
| Other undisclosed current liabilities | 75 | 277 | 2,398 | 1,058 | 1,673 | 3,301 | ||
| Total current liabilities: | 5,465 | 5,820 | 5,900 | 5,723 | 5,858 | 7,551 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 31 | 79 | ||||||
| Operating lease, liability | 31 | 79 | ||||||
| Total noncurrent liabilities: | 62 | 158 | ||||||
| Total liabilities: | 5,465 | 5,820 | 5,900 | 5,785 | 5,858 | 7,709 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 88,120 | 94,476 | 102,519 | 108,303 | 112,951 | 15,700 | ||
| Common stock | 49 | 49 | 49 | 49 | 49 | 22 | ||
| Additional paid in capital | 202,201 | 200,484 | 198,897 | 196,999 | 195,699 | 95,918 | ||
| Accumulated deficit | (114,130) | (106,057) | (96,427) | (88,745) | (82,797) | (80,240) | ||
| Total stockholders' equity: | 88,120 | 94,476 | 102,519 | 108,303 | 112,951 | 15,700 | ||
| Other undisclosed liabilities and equity | (31) | 143 | ||||||
| TOTAL LIABILITIES AND EQUITY: | 93,585 | 100,296 | 108,419 | 114,057 | 118,809 | 23,552 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 556 | 2,128 | 883 | 748 | 1,588 | 585 | |
| Gross profit: | 556 | 2,128 | 883 | 748 | 1,588 | 585 | |
| Operating expenses | (8,636) | (11,765) | (8,573) | (6,707) | (4,449) | (4,980) | |
| Operating loss: | (8,080) | (9,637) | (7,690) | (5,959) | (2,861) | (4,395) | |
| Nonoperating income | 40 | 7 | 8 | 11 | 307 | ||
| Investment income, nonoperating | 7 | 8 | 11 | 3 | |||
| Other nonoperating income | 304 | ||||||
| Loss before gain (loss) on sale of properties: | (8,040) | (9,630) | (7,682) | (5,948) | (2,554) | (4,395) | |
| Other undisclosed net loss | (33) | (3) | |||||
| Net loss available to common stockholders, diluted: | (8,073) | (9,630) | (7,682) | (5,948) | (2,557) | (4,395) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (8,073) | (9,630) | (7,682) | (5,948) | (2,557) | (4,395) | |
| Comprehensive loss, net of tax, attributable to parent: | (8,073) | (9,630) | (7,682) | (5,948) | (2,557) | (4,395) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.